Is Tema Cardiovascular and Metabolic ETF (HRTS) a Buy, Sell, or Hold?
NASDAQ : HRTS
Tema Cardiovascular and Metabolic ETF
$36.565 USD
$0.17 (0.46%)
- Volume
- 3.71K
- Average Volume
- 5.33K
- Market Capitalization
- $54.94M
- P/E Ratio
- Dividend Yield
- %
- Price Target
- Year High
- $37.58
- Year Low
- $27.24
- Day High
- —
- Day Low
- —
- Payout Ratio
- Current Ratio
Company Overview
NASDAQ
None
Asset Management
Financial Services
HRTS
N/A
US
USD
Liquidity Metrics
Sales & Valuation
-$
Profitability
-$
%
%
%
%
P/E Metrics
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
No financial score data available.
Key Metrics (TTM)
No key metrics data available.
Company Executives
No executive data available.
Poll Results
No votes yet today — be the first to share your view!
About Tema Cardiovascular and Metabolic ETF (NASDAQ:HRTS) Stock
The Tema Heart & Health ETF (HRTS) is designed to strategically invest in companies poised to benefit from cutting-edge developments within the biotechnology and broader healthcare industries. Its investment mandate specifically targets firms focused on advancing treatments and therapies for cardiovascular health, metabolic disorders, and weight management. ...
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
2026-07-01 09:16:09
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Tema ETFs Exceeds $5bn in AUM After Three Years
2026-06-15 09:51:00
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
2026-06-10 13:01:19
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
2026-05-19 15:31:07
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
Frequently Asked Questions
-
What is the current Tema Cardiovascular and Metabolic ETF (HRTS) stock price?
-
Tema Cardiovascular and Metabolic ETF(NASDAQ:HRTS) stock price is $36.565 in the last trading session. During the trading session, HRTS stock reached the peak price of $37.575 while $27.235 was the lowest point it dropped to. The percentage change in HRTS stock occurred in the recent session was 0.46% while the dollar amount for the price change in HRTS stock was $0.17.
-
HRTS's industry and sector of operation?
-
The NASDAQ listed HRTS is part of Asset Management industry that operates in the broader Financial Services sector.
-
Who are the executives of HRTS?
-
|
|
|
|
| -
How many employees does HRTS have?
-
Number of HRTS employees currently stands at None. HRTS operates from Brookfield Place, 200 Vesey Street, Suite 24106, New York, NY 10281, US.
-
Link for HRTS official website?
-
Official Website of HRTS is: https://temaetfs.com/hrts
-
How do I contact HRTS?
-
HRTS could be contacted at phone #1-302-499-4928 and can also be accessed through its website. HRTS operates from Brookfield Place, 200 Vesey Street, Suite 24106, New York, NY 10281, US.
-
How many shares of HRTS are traded daily?
-
The average number of HRTS shares traded daily for last 3 months was 5.33K.
-
What is the market cap of HRTS currently?
-
The market value of HRTS currently stands at $54.94M with its latest stock price at $36.565